Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

GOLD Document

Fig. 04 -

Community

Fig. 05 -

Realize

Fig. 06 -

Not Enough Time

Fig. 07 -

Evolution

Fig. 08 -

Pharmacotherapy

Fig. 09 -

Subgroup Rate

Fig. 10 -

Example

Fig. 11 -

Example (cont.)

Fig. 12 -

Goals for Treatment

Fig. 13 -

Table 4.8.

Fig. 14 -

Benefit - Risk

Fig. 15 -

Modification

Fig. 16 -

Strategy Document

Fig. 17 -

Improve Breathlessness

Fig. 18 -

Persistent Symptoms

Fig. 19 -

LAMA and LABA

Fig. 20 -

Symptomatic Response

Fig. 21 -

Further Exacerbation(s)

Fig. 22 -

LAMA vs LABA

Fig. 23 -

LAMA + LABA + ICS

Fig. 24 -

Table 4.6.

Fig. 25 -

Decreased Exacerbations

Fig. 26 -

LABA/LAMA vs ICS/LABA

Fig. 27 -

LAMA + LABA

Fig. 28 -

Roflumilast and Macrolide

Fig. 29 -

Group D

Fig. 30 -

Triple Therapy

Fig. 31 -

Roflumilast and Macrolide

Fig. 32 -

Step down is possible

Fig. 33 -

ICS Withdrawn

Fig. 34 -

Table 4.9.

Fig. 35 -

Treatment of Hypoxemia

Fig. 36 -

LTOT in Mod. Hypoxemia

Fig. 37 -

LTOT vs No LTOT

Fig. 38 -

Spirometry

Fig. 39 -

Bronchoscopy and Surgery

Fig. 40 -

Surgical & Interventional Therapies

Fig. 41 -

Key Points